دورية أكاديمية
أعرض في EDS

Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention.

التفاصيل البيبلوغرافية
العنوان: Chromatin Complexes Maintain Self-Renewal of Myeloid Progenitors in AML: Opportunities for Therapeutic Intervention.
المؤلفون: Uckelmann HJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA., Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: scott_armstrong@dfci.harvard.edu.
المصدر: Stem cell reports [Stem Cell Reports] 2020 Jul 14; Vol. 15 (1), pp. 6-12. Date of Electronic Publication: 2020 Jun 18.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Cell Press Country of Publication: United States NLM ID: 101611300 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-6711 (Electronic) Linking ISSN: 22136711 NLM ISO Abbreviation: Stem Cell Reports Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Cambridge, MA] : Cell Press, c 2013-
مواضيع طبية MeSH: Cell Self Renewal*, Chromatin/*metabolism , Leukemia, Myeloid, Acute/*pathology , Myeloid Progenitor Cells/*pathology, Humans ; Leukemia, Myeloid, Acute/drug therapy ; Molecular Targeted Therapy ; Neoplastic Stem Cells/pathology
مستخلص: Specific subgroups of acute myeloid leukemia (AML), including those containing MLL rearrangements and NPM1c mutations, possess characteristic stem cell-like gene expression profiles. These expression programs are highly dependent on components of the MLL histone methyltransferase complex, including Menin and DOT1L. Understanding the chromatin-based mechanisms through which cancer cells subvert certain aspects of normal stem cell biology helped identify specific vulnerabilities and translate them into targeted therapy approaches. Exciting progress has been made in the development of small-molecule inhibitors targeting this epigenetic machinery in leukemia cells and prompted the development of clinical trials in patients with hematologic malignancies.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
References: Arch Pathol Lab Med. 2017 Nov;141(11):1462-1468. (PMID: 29072953)
Blood. 2011 May 5;117(18):4759-68. (PMID: 21398221)
Cancer Res. 2010 Dec 15;70(24):10234-42. (PMID: 21159644)
Oncogene. 2004 Sep 20;23(43):7164-77. (PMID: 15378077)
Nature. 2000 Mar 9;404(6774):193-7. (PMID: 10724173)
Curr Biol. 2002 Jun 25;12(12):1052-8. (PMID: 12123582)
Science. 2020 Jan 31;367(6477):586-590. (PMID: 32001657)
Genes Dev. 2011 Jul 1;25(13):1345-58. (PMID: 21724828)
N Engl J Med. 2005 Jan 20;352(3):254-66. (PMID: 15659725)
Nature. 2018 Jan 11;553(7687):212-216. (PMID: 29323290)
Nat Commun. 2016 Jul 11;7:12166. (PMID: 27397025)
Br J Haematol. 2013 Sep;162(5):670-7. (PMID: 23826732)
Leukemia. 2015 Jun;29(6):1279-89. (PMID: 25600023)
Blood. 2013 Mar 28;121(13):2533-41. (PMID: 23361907)
Science. 1988 Jul 1;241(4861):58-62. (PMID: 2898810)
Cell Stem Cell. 2015 Oct 1;17(4):422-34. (PMID: 26299573)
Genes Dev. 2008 Dec 15;22(24):3403-8. (PMID: 19141473)
Cancer Cell. 2004 Dec;6(6):587-96. (PMID: 15607963)
Cancer Cell. 2014 Dec 8;26(6):896-908. (PMID: 25464900)
Cancer Cell. 2011 Jul 12;20(1):66-78. (PMID: 21741597)
Nat Rev Immunol. 2011 Sep 09;11(10):685-92. (PMID: 21904387)
Blood. 2018 Jun 14;131(24):2661-2669. (PMID: 29724899)
Mol Cell. 2010 Feb 12;37(3):429-37. (PMID: 20159561)
J Clin Invest. 2020 Feb 3;130(2):981-997. (PMID: 31855575)
Nature. 2009 Apr 16;458(7240):904-8. (PMID: 19212321)
Cancer Cell. 2015 Apr 13;27(4):589-602. (PMID: 25817203)
J Biol Chem. 2004 Mar 12;279(11):10685-91. (PMID: 14688275)
Leukemia. 2017 Jun;31(6):1269-1277. (PMID: 27840424)
J Biol Chem. 2004 Nov 19;279(47):49045-54. (PMID: 15331604)
Leukemia. 2013 Apr;27(4):852-60. (PMID: 23235717)
Cancer Discov. 2016 Oct;6(10):1166-1181. (PMID: 27535106)
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1018-23. (PMID: 16415155)
Cancer Cell. 2016 Jun 13;29(6):922-934. (PMID: 27300438)
Cancer Cell. 2008 Nov 4;14(5):355-68. (PMID: 18977325)
N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137)
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54. (PMID: 15640349)
Cancer Cell. 2019 Dec 9;36(6):660-673.e11. (PMID: 31821784)
Nature. 2006 Aug 17;442(7104):818-22. (PMID: 16862118)
Leukemia. 2018 Feb;32(2):273-284. (PMID: 28701730)
Cell. 2013 Aug 29;154(5):1112-1126. (PMID: 23993099)
Nat Med. 2015 Apr;21(4):335-43. (PMID: 25822366)
N Engl J Med. 2017 Jul 13;377(2):111-121. (PMID: 28636844)
Genes Dev. 2003 Dec 15;17(24):3029-35. (PMID: 14701873)
Cell. 2000 Jan 7;100(1):57-70. (PMID: 10647931)
Cancer Cell. 2017 Jun 12;31(6):755-770.e6. (PMID: 28609655)
J Clin Oncol. 2013 Jan 1;31(1):95-103. (PMID: 23008312)
Cell. 2005 Oct 21;123(2):207-18. (PMID: 16239140)
Nature. 2015 Apr 23;520(7548):549-52. (PMID: 25707806)
Nature. 2018 Jul;559(7714):400-404. (PMID: 29988082)
Cell Rep. 2014 May 22;7(4):1239-47. (PMID: 24813891)
Am J Cancer Res. 2019 Aug 01;9(8):1682-1694. (PMID: 31497350)
Nat Med. 2018 Jul;24(7):1015-1023. (PMID: 29988143)
Leukemia. 2013 Apr;27(4):813-22. (PMID: 23138183)
Blood. 2013 Sep 19;122(12):2039-46. (PMID: 23908472)
معلومات مُعتمدة: P01 CA066996 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Chromatin)
تواريخ الأحداث: Date Created: 20200620 Date Completed: 20210602 Latest Revision: 20210602
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7363875
DOI: 10.1016/j.stemcr.2020.05.013
PMID: 32559456
قاعدة البيانات: MEDLINE
الوصف
تدمد:2213-6711
DOI:10.1016/j.stemcr.2020.05.013